We are live on
!
Find out more
AA
Alta Advisers Portfolio holdings
AUM
$276M
1-Year Est. Return
26.84%
This Fund
S&P 500
This Quarter
Est. Return
-1.45%
1 Year Est. Return
+26.84%
3 Year Est. Return
+78.95%
5 Year Est. Return
+85.66%
10 Year Est. Return
–
AUM
$144M
AUM Growth
+$13M
(+9.9%)
Cap. Flow
+$13.9M
Cap. Flow
% of AUM
9.64%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
1
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$13.6M |
| 2 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$789K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$476K |
| 2 |
Vanguard Short-Term Treasury ETF
VGSH
|
+$39.5K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 8.94% |
Similar funds
EFP
TLA
MC
IIA
AWA
RCA
TAP
1NWS
Alta Advisers's Q3 2019 Portfolio in Review
As of Q3 2019, Alta Advisers held 4 positions worth $144M, up 9.9% from $131M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Alta Advisers deployed $13.9M of net new capital in Q3 2019, opening 1 new position and adding to 1 existing holding. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 160,628 shares worth $12.9M.
By sector, the portfolio is most concentrated in Healthcare at 8.9% of assets.
On the sell side, the largest reduction was Vanguard S&P 500 ETF, an estimated $476K trimmed.
- Alta Advisers's largest Q3 2019 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 160,628 shares worth $12.9M.
- Alta Advisers added most to Vanguard FTSE All-World ex-US ETF in Q3 2019, an estimated $789K increase.
- Alta Advisers's biggest Q3 2019 reduction was Vanguard S&P 500 ETF, cutting an estimated $476K.
- Alta Advisers's ten largest holdings make up 100% of its $144M portfolio in Q3 2019.
- Alta Advisers opened 1 new position and closed 0 in Q3 2019.
- Alta Advisers's portfolio value rose 9.9% quarter-over-quarter to $144M.
Based on Alta Advisers's 13F filing for Q3 2019, filed 5 Nov 2019.